COMMENTED ARTICLES

Search for:
to
x clear all filters
NASH and post-transplant metabolic syndrome
The presence or recurrence of metabolic syndrome following liver transplantation can contribute to the development and recurrence of NAFLD in the liver allograft…
Reviewed by
G. Bozet, MD
Authors
Spiritos Z, Abdelmalek MF.
Published in
Transl Gastroenterol Hepatol 2021
Read more
Insulin resistance in MAFLD
Many studies have reported that metabolic dysfunction is closely involved in the complex mechanism underlying the development of NAFLD. This has prompted a movement to consider renaming NAFLD as metabolic dysfunction-associated fatty liver disease…
Reviewed by
D. Beard
Authors
Sakurai Y, Kubota N, Yamauchi T, et al.
Published in
Int J Mol Sci 2021
Read more
NATIVE: first clinical trial demonstrating…
Treatment options for NASH are limited. S. M. Francque et al. (Antwerp University Hospital, Belgium) examined the effects of lanifibranor, a pan-agonist of the peroxisome proliferator–activated receptors with favourable effects on glucose and lipid metabolism, inflammation, and fibrosis, in 247 patients with active, noncirrhotic NASH…
Reviewed by
G. Bozet, MD
Authors
Francque SM, Bedossa P, Ratziu V, et al.
Published in
N Engl J Med 2021
Read more
Lanifibranor in NASH: NATiV3, an ongoing phase 3 trial
The New England Journal of Medicine has published the results of the NATIVE Phase IIb clinical trial with lanifibranor in NASH. Lanifibranor met both the primary and key secondary endpoints, including NASH resolution with no worsening of fibrosis and improvement of liver fibrosis with no worsening of NASH…
Reviewed by
D. Beard
Authors
Garcia-Tsao G.
Published in
N Engl J Med 2021
Read more
Outcomes in adults with NAFLD
Given the growing importance of NAFLD and its inflammatory manifestation, in a new prospective study from the NASH Clinical Research Network, A. J. Sanyal et al. describe outcomes for 1773 adults with biopsy-proven NAFLD with an average follow-up period of 4 years…
Reviewed by
G. Bozet, MD
Authors
Sanyal AJ, Van Natta ML, Clark J, et al.
Published in
N Engl J Med 2021
Read more
New targets for NAFLD
NAFLD is a growing cause of chronic liver disease worldwide. Several preclinical models (dietary and genetic animal models) of NAFLD have deepened our understanding of its aetiology and pathophysiology. Despite the progress made, there are currently no effective treatments for NAFLD…
Reviewed by
D. Beard
Authors
Parlati L, Régnier M, Guillou H, et al.
Published in
JHEP Rep 2021
Read more
NAFLD and incident dementia in elderly patients
An association between NAFLD and brain aging has been suggested. Therefore, C. Labenz et al. aimed to investigate the hypothesis if NAFLD is an independent risk factor for emerging dementia…
Reviewed by
G. Bozet, MD
Authors
Labenz C, Kostev K, Kaps L, et al.
Published in
Dig Dis Sci 2021
Read more
Obese NAFLD children and adolescents: high BMI predicts liver fibrosis
H. Moran-Lev et al. (Dana Dwek Children’s Hospital, Tel Aviv University, Israel) aimed to investigate the predictors for liver fibrosis and the effects of short-term nutritional intervention on steatosis and fibrosis among obese adolescents with NAFLD…
Reviewed by
D. Beard
Authors
Moran-Lev H, Cohen S, Webb M, et al.
Published in
BMC Pediatr 2021
Read more
NAFLD in the elderly
The diagnosis and management strategies of NAFLD in older adults are sometimes challenging, and certain age-specific factors have to be taken into account. In this review, S. A. Alqahtani (King Faisal Specialist Hospital & Research Center, Saudi Arabia and Johns…
Reviewed by
G. Bozet, MD
Authors
Alqahtani SA, Schattenberg JM.
Published in
Clin Interv Aging 2021
Read more
NAFLD and incident chronic kidney disease
The association of NAFLD and CKD has been established before. The aim of this large-scale database study was to investigate the role of NAFLD on emerging CKD, the emergence of end-stage renal disease and the identification of additional risk factors which may increase the risk for CKD in Germany…
Reviewed by
D. Beard
Authors
Kaps L, Labenz C, Galle PR, et al.
Published in
United European Gastroenterol J 2020
Read more
Hepatocellular carcinoma diagnosis and quality of life
M. Verma et al. (Inova Fairfax Medical Campus, Inova Health System, USA) aimed to compare hepatocellular cancer cases with matched controls to evaluate the differences in change in quality of life from before to after hepatocellular cancer diagnosis, using the Medical Outcomes Study Short Form-36…
Reviewed by
G. Bozet, MD
Authors
Verma M, Paik JM, Younossi I, et al.
Published in
Cancer Med 2021
Read more
Diabetic kidney disease, cardiovascular disease and NAFLD
NAFLD, cardiovascular disease and chronic kidney disease share a common pathophysiology including insulin resistance, oxidative stress, chronic inflammation, dysbiosis and genetic susceptibilities. The aim of this review by C. M. Perdomo et al…
Reviewed by
D. Beard
Authors
Perdomo CM, Garcia-Fernandez N, Escalada J.
Published in
J Clin Med 2021
Read more
Awareness related to NAFLD in Mexican-origin women
Mexican-origin women suffer disproportionate rates of NAFLD. The purpose of this study by K. E. Morrill et al. (University of Arizona Cancer Center, USA) was to assess awareness, knowledge, perceptions, and information sources related to NAFLD in a community-based sample of Mexican-origin women. Qualitative findings revealed low…
Reviewed by
G. Bozet, MD
Authors
Morrill KE, Crocker RM, Hingle MD, et al.
Published in
Front Public Health 2021
Read more
Chronic vitamin C deficiency decreases NAFLD progression
Senescence marker protein 30 (SMP30) is a multifunctional protein involved in cellular Ca2+ homeostasis and the biosynthesis of ascorbate in non-primate mammals. It was recently recognised as a gluconolactonase. Vitamin C had definite effects on lipid metabolism, but the precise relation between vitamin C and lipid metabolism…
Reviewed by
D. Beard
Authors
Lee SW, Baek SM, Kang KK, et al.
Published in
Am J Pathol 2021
Read more
NAFLD and carotid Intima-media thickness in Nepal
The incidence of cardiovascular disease is higher in NAFLD as compared to those without NAFLD and studies have shown it being as a predictor of cardiovascular disease and independent of conventional risk factors. The objective of this descriptive cross-sectional study by B. Bc (7 Rapti Academy of Health Sciences, Dang, Nepal) was to find…
Reviewed by
G. Bozet, MD
Authors
Bc B, Jaiswal RK, Gupta PK, et al.
Published in
JNMA J Nepal Med Assoc 2021
Read more
MAFLD: brain-gut-liver axis and insulin resistance
There are many complex physio-pathologic connections within the brain, gut, and liver axis. This review by E. Rebelos et al. (University of Turku, Finland) is focused on the early pathophysiology of brain, gut, and liver axis in the context of insulin resistance and specifically addresses two pillars of hepatic insulin resistance….
Reviewed by
D. Beard
Authors
Rebelos E, Iozzo P, Guzzardi MA, et al.
Published in
World J Gastroenterol 2021
Read more
Asia, Middle East, North Africa: burden of NAFLD
Using Global Burden of Disease data, P. Golabi et al. (Inova Health System, USA) aimed to assess the incidence, mortality, and disability-adjusted life years attributable to NAFLD-related liver complications in Asia, the Middle East and North Africa. As stated by the authors in their conclusion, “NAFLD is poised to contribute to a substantial…
Reviewed by
G. Bozet, MD
Authors
Golabi P, Paik JM, AlQahtani S, et al.
Published in
J Hepatol 2021
Read more
FIB-4 and NFS: which performance?
M. Castellana et al. (National Institute of Gastroenterology “Saverio de Bellis,” Research Hospital, Italy) conducted a meta-analysis to assess the performance of the FIB-4 and NFS scores, the 2 most common non-invasive tools, for the appropriate selection of subjects with AF for biopsy. A total of 18 studies evaluating 12,604 subjects were included…
Reviewed by
D. Beard
Authors
Castellana M, Donghia R, Guerra V, et al.
Published in
Am J Gastroenterol 2021
Read more
NAFLD/NASH: clinical, economical, and patient related burdens
Given the obesity epidemic, NAFLD and NASH have reached alarming levels globally. Recent data suggest that more than a quarter of the world population is affected by NAFLD, however, the disease prevalence is higher in certain patient population, i.e. among patients with type 2 diabetes. The growing global burden of NAFLD has…
Reviewed by
G. Bozet, MD
Authors
Kabarra K, Golabi P, Younossi ZM.
Published in
Endocr Connect 2021
Read more
Enhanced liver fibrosis test and recognition of liver fibrosis
This retrospective cross-sectional study was conducted among patients recruited from a large, community-based hospital system’s outpatient liver clinic from 2001 to 202 in order to determine the performance of the enhanced liver fibrosis (ELF) test as a non-invasive test for assessment of liver fibrosis among patients with NAFLD…
Reviewed by
D. Beard
Authors
Younossi ZM, Felix S, Jeffers T, et al.
Published in
JAMA Netw Open 2021
Read more
NASH Epidemic: a call to action
NAFLD and NASH are common conditions with a rising burden. As pointed out by F. Kanwal et al. (Baylor College of Medicine, and Michael E. DeBakey Veterans Affairs Medical Center, Houston,USA), “yet there are significant management gaps between clinical guidelines and practice in patients with NAFLD and NASH. Further, there is no single…
Reviewed by
D. Beard
Authors
Kanwal F, Shubrook JH, Younossi Z, et al.
Published in
Gastroenterology 2021
Read more
NAFLD and acute stroke: factors associated at admission
This retrospective study by T. Mori et al. (Shanghai Jiao Tong University School of Medicine, China) aimed to investigate NAFLD frequency and identify factors associated with NAFLD presence at acute stroke admission.

The authors included stroke patients admitted from 2016 to 2019, within 24 h of onset…

Reviewed by
G. Bozet, MD
Authors
Mori T, Yoshioka K, Tanno Y.
Published in
Hepatol Int 2021
Read more
NAFLD unawareness in US adults
MAFLD is closely related to disturbances in systemic energy metabolism, including insulin resistance and atherogenic dyslipidaemia. This review by J. Heeren and L Scheja (University Medical Center Hamburg-Eppendorf, Germany) discusses recent research addressing lipoprotein metabolism in the context of MAFLD…
Reviewed by
G. Bozet, MD
Authors
Alqahtani SA, Paik JM, Biswas R, et al.
Published in
Mol Metab 2021
Read more
MAFLD and lipoprotein metabolism
MAFLD is closely related to disturbances in systemic energy metabolism, including insulin resistance and atherogenic dyslipidaemia. This review by J. Heeren and L Scheja (University Medical Center Hamburg-Eppendorf, Germany) discusses recent research addressing lipoprotein metabolism in the context of MAFLD…
Reviewed by
D. Beard
Authors
Heeren J, Scheja L.
Published in
Mol Metab 2021
Read more
Hydrogen sulfide and NAFL
Nowadays, H2 S is recognised as the third mammalian gasotransmitter. It plays an important role in inflammation, septic shock, ischaemia reperfusion events, cardiovascular disease, and in liver physiology and chronic liver diseases such as NAFLD. This narrative review shows that H2 S emerges as a key regulator of liver metabolism…
Reviewed by
G. Bozet, MD
Authors
Mateus I, Prip-Buus C.
Published in
Eur J Clin Invest 2021
Read more
Identifying patients with high-risk NASH: three ultrasound markers
Identifying patients with high-risk-NASH who are candidates for pharmacologic therapy remains a challenge. K. Sugimoto et al. (Tokyo Medical University, Japan) aimed to develop a score to identify patients with a NAFLD activity score of 4 or greater and clinically significant fibrosis…
Reviewed by
D. Beard
Authors
Sugimoto K, Lee DH, Lee JY, et al.
Published in
Radiology 2021
Read more
Endolysosomal network and MAFLD
Emerging evidence has shown that the endolysosomal network is crucial to maintain metabolic homeostasis. In this review, D. Y. Vos et al. summarise the current understanding of the role of the endolysosomal network in cholesterol homeostasis and its implications in MAFLD pathogenesis….
Reviewed by
G. Bozet, MD
Authors
Vos DY, van de Sluis B.
Published in
Mol Metab 2021
Read more
Genetic and epigenetic factors determining NAFLD risk
Predicting the individual risk of NAFLD and determining the probability of disease progression is the basis for further developing prevention and treatment strategies. This requires knowledge of the genetic and epigenetic modifiers of NAFLD for genotype-guided risk stratification…
Reviewed by
D. Beard
Authors
Jonas W, Schurmann A.
Published in
Mol Metab 2021
Read more
A link between hyperuricemia and NAFLD
An elevated level of plasma uric acid has been widely recognised as a risk factor for NAFLD, where oxidative stress and inflammation play an important role in the pathophysiology of the disease. Although the complete molecular mechanisms involved remain unknown, while under physiological conditions uric acid presents antioxidant properties…
Reviewed by
G. Bozet, MD
Authors
Toledo-Ibelles P, Gutiérrez-Vidal R, Calixto-Tlacomulco S, et al.
Published in
Arch Med Res 2021
Read more
Hepatic lipid droplets and metabolic dysfunction in NAFLD
Historically considered simply depots for energy storage, lipid droplets are increasingly recognised to impact a wide range of biological processes. Lipid droplets accumulation (or steatosis) and progression to advanced stages of NAFLD remains to be resolved…
Reviewed by
D. Beard
Authors
Mashek DG.
Published in
Mol Metab 2021
Read more
NAFLD risk factors after antiviral treatment for hepatitis C
J. N. Benhammou et al. (University of California Los Angeles, and VA Greater Los Angeles Healthcare System, USA) aimed to determine whether diabetes and/or obesity are associated with adverse outcomes in direct-acting antiviral-treated HCV patients…
Reviewed by
G. Bozet, MD
Authors
Benhammou JN, Moon AM, Pisegna JR, et al.
Published in
Dig Dis Sci 2021
Read more
Increased plasma XOR activity induced by NAFLD/NASH and its possible involvement in vascular neointimal proliferation
Xanthine oxidoreductase is an enzyme that catalyses hypoxanthine to xanthine and xanthine to uric acid, respectively. However, the underlying mechanisms of increased plasma xanthine oxidoreductase and its pathological roles in systemic diseases, such as atherosclerosis, are not fully understood…
Reviewed by
D. Beard
Authors
Kawachi Y, Fujishima Y, Nishizawa H, et al.
Published in
JCI Insight 2021
Read more